Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

NCT06672952 | Recruiting

• 1 other identifier: IRB-24-82
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.

Conditions

Exercise Performance; Exercise Recovery; Cognitive Function; Nitric Oxide; Blood Flow; Endurance Exercise

Keywords

exercise performance; aerobic capacity; anaerobic power; mood; nitric oxide; cognitive function; glucosyl-hesperidin; training readiness; fuel utilization; endothelial function

Outcome Measures

Primary Outcomes (6)

• Change from Baseline in Peak VO2 at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  Peak VO2 will be measured as an indicator of maximal aerobic capacity. Higher values reflect improved cardiovascular performance.

  Baseline and Week 8

• Change from Baseline in Wingate Anaerobic Test Peak Anaerobic Power at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  Peak anaerobic power will be measured to assess maximal power output during high-intensity exercise. Higher values indicate improved anaerobic performance.

  Baseline and Week 8

• Change from Baseline in Wingate Anaerobic Test Mean Anaerobic Power at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  Wingate Anaerobic Test Mean anaerobic power will be recorded during repeated high-intensity exercise, with higher values indicating enhanced anaerobic endurance.

  Baseline and Week 8

• Change from Baseline in Fatigue Rate at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  Wingate Anaerobic Test Fatigue rate will be measured as the decline in power over time during anaerobic exercise, with a lower rate indicating improved endurance.

  Baseline and Week 8

• Change from Baseline in Perceived Indicators of Recovery, Training Readiness, Soreness, and Overall Feel Using Visual Analog Scales (VAS) at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  Perceived recovery, training readiness, soreness, recovery, and general "feel" will be self-rated using visual analog scales (VAS), with higher values indicating greater perceived improvements in each category.

  Baseline and Week 8

• Change from Baseline in Brachial Artery Blood Flow Measured 0, 30, and 60 Minutes After Acute and Prolonged Ingestion of Glucosyl-Hesperidin (CITRAPEAK)

  Brachial artery blood flow will be measured to assess vascular response to CITRAPEAK at baseline and after 8 weeks of supplementation, with measurements taken at 0, 30, and 60 minutes post-ingestion.

  Baseline and Week 8, measured at 0, 30, and 60 minutes post-ingestion.

Secondary Outcomes (6)

• Change from Baseline in Carbohydrate and Fat Oxidation Rates at 30%, 40%, 50%, 60%, 70%, and 80% Peak VO2 During Exercise at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  Baseline and Week 8

• Change from Baseline in Stroop Color Matching Test Performance 0, 30, and 60 Minutes After Ingesting Dose 1 (Week 0) and Dose 56 (Week 8) Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  0, 30, and 60 minutes post-ingestion at baseline and Week 8

• Change from Baseline in Trail Making Test Performance 0, 30, and 60 Minutes After Ingesting Dose 1 (Week 0) and Dose 56 (Week 8) Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  0, 30, and 60 minutes post-ingestion at baseline and Week 8

• Change from Baseline in Profile of Mood States (POMS) Score at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  Baseline and Week 8

• Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation

  Baseline and Week 8

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Participants in this arm will receive a placebo supplement consisting of 400 mg of cellulose per day. The placebo is designed to match the appearance and dosage form of the active interventions, allowing for blinding in the study.

Dietary Supplement: Placebo

200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

EXPERIMENTAL

Participants in this arm will receive a total of 200 mg of glucosyl-hesperidin (CITRAPEAK®) supplementation per day, along with an additional 200 mg of cellulose. This will provide a daily dosage of 400 mg, maintaining blinding to ensure the placebo effect is accounted for.

Dietary Supplement: 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

EXPERIMENTAL

Participants in this arm will receive a total of 400 mg of glucosyl-hesperidin (CITRAPEAK®) supplementation per day. This higher dose is intended to evaluate its effects on exercise performance, recovery, and cognitive function compared to the placebo and lower dose.

Dietary Supplement: 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

Interventions

200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation DIETARY_SUPPLEMENT

The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.

200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation DIETARY_SUPPLEMENT

The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.

400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

Placebo DIETARY_SUPPLEMENT

The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.

Placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants who are between 18 - 50 years of age
• Body mass index values will range from \>25.0 \< 30.0 kg/m2
• The average body mass index for entire study cohort will be less than 27.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg/m2
• Free-living and independent
• In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders
• Willingness to maintain consistent sleep duration the evening before study visits
• Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures
• Regular completion of at least 180 minutes of moderate to vigorous exercise per week for the past 6 months

You may not qualify if:

• Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months
• Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease
• Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals
• Has liver disease or some form of clinically diagnosed hepatic impairment
• Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \> 126 mg/dL)
• Diagnosed with or is being treated for some form of thyroid disease
• Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year
• Diagnosed with some form of immune disorder (i.e., HIV/AIDS)
• History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).
• Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
• Positive medical history for any neurological condition or neurological disease
• Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.)
• Current smoker (average of \> 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine
• Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc.
• Participants who are lactating, pregnant or planning to become pregnant

Sponsors & Collaborators

• Lindenwood University: lead
• Increnovo, LLC: collaborator

Study Sites (1)

Lindenwood University

Saint Charles, Missouri, 63301, United States

RECRUITING

MeSH Terms

Interventions

glucosyl hesperidin; Dietary Supplements

Intervention Hierarchy (Ancestors)

Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Study Officials

• Chad M Kerksick, PhD

  Lindenwood University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Anthony M Hagele, MS

CONTACT

636-949-4785; ahagele@lindenwood.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: This study employs a double-blind design to ensure that participants, investigators, and outcome assessors remain unaware of the group assignments. All supplements (placebo and both doses of CITRAPEAK®) are provided in identical capsules, containing either 400 mg of cellulose (placebo), 200 mg of CITRAPEAK® with 200 mg of cellulose, or 400 mg of CITRAPEAK®. Each participant is assigned a unique randomization code, which is used to label the capsules, maintaining blinding throughout the study. Only the study designated unblinded personnel have access to the randomization key, ensuring that the blinding remains intact for all other study staff.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 1, 2024
• First Posted: November 4, 2024
• Study Start: April 15, 2025
• Primary Completion: January 1, 2026
• Study Completion: January 1, 2026
• Last Updated: December 12, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)